Replies to post #169196 on Biotech Values

[oc631]

Even if the oral had been 10% less potent, would you not prefer it?

Even 15% lower efficacy would be a fair trade off IMO.


I'm anxious to see the results from the Phase-3B study comparing both options.

[oc631]

Even if the oral had been 10% less potent, would you not prefer it?

There's no question if I was a HCV patient I would want oral treatment first. Since I follow the space as an investor I would choose to wait (if able) for a better oral option than Sofo/Riba. I've seen results range from 30% SVR rates at 12-weeks to 85% at 24-weeks in open-label studies. Once Sofo/Riba gets approved we will get a better read on Sofo/GS-5816.